首页>
外国专利>
Combination of progesterone receptor antagonists with lutein hormone releasing hormone agonists and antagonists for use in BRCA mediated diseases
Combination of progesterone receptor antagonists with lutein hormone releasing hormone agonists and antagonists for use in BRCA mediated diseases
展开▼
机译:孕激素受体拮抗剂与叶黄素激素释放激素激动剂和拮抗剂的组合,用于BRCA介导的疾病
展开▼
页面导航
摘要
著录项
相似文献
摘要
The present invention relates to the combination of the progesterone-receptor antagonist 11beta-(4-acetylphenyl)-17beta-hydroxy-17alpha-(1,1,2,2,2-pentafluoroethyl)-estra-4,9-dien-3-one or a pharmaceutically acceptable derivative or analogue thereof, together with at least one lutein-hormone-releasing hormone agonist or antagonist and to the use of said combination for the prophylaxis and treatment of BRCA1- or BRCA2-mediated diseases. Lutein-hormone-releasing hormone agonists and antagonists, which can be combined together with the compound 11beta-(4-acetylphenyl)-17beta-hydroxy-17alpha-(1,1,2,2,2 pentafluoroethyl)-estra-4,9-dien-3-one are for example gonadorelin, goserelin, triptorelin, buserelin, nafarelin, deslorelin, histrelin, antide, ramorelix, cetrorelix, antarelix, ORG30850, abarelix, ganirelix and leuprolin.
展开▼